And, now, the worst CEOs
Yesterday, STAT’s Adam Feuerstein invited you to vote on the best biopharma CEOs of the year. Today brings the inverse.
This year’s nominees for worst CEO represent companies big and small, storied and newfangled. There’s an executive who has presided over two major restructurings while somehow keeping his job. There’s one who promised a big-money buyout that has never come through. And there’s the leader of a unicorn that has managed to miss all of its promised deadlines since going public at a $2 billion valuation.
As always, this survey not based on data science, machine learning, or really anything measurable. It’s supposed to be fun. Vote here.
This year’s nominees for worst CEO represent companies big and small, storied and newfangled. There’s an executive who has presided over two major restructurings while somehow keeping his job. There’s one who promised a big-money buyout that has never come through. And there’s the leader of a unicorn that has managed to miss all of its promised deadlines since going public at a $2 billion valuation.
As always, this survey not based on data science, machine learning, or really anything measurable. It’s supposed to be fun. Vote here.
No hay comentarios:
Publicar un comentario